TriangleFGFR4-CAR T Cells (NCT06865664)
FGFR4-CAR T Cells trial for Rhabdomyosarcoma (NCT06865664). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Rhabdomyosarcoma is the most common soft tissue cancer in children. Low-risk disease is usually cured; when it comes back, fewer than one in five survive five years.
The idea: every rhabdomyosarcoma cell carries the same surface receptor, so aim engineered T cells at it.
That receptor is FGFR4. NCI researchers showed it sits on essentially all rhabdomyosarcomas and drives the most aggressive form, so it need not even be tested. A patient's T cells are collected, given a receptor for FGFR4, and returned in one infusion after four days of chemotherapy clears space.
A first dose-finding study, ages three to thirty-nine, after at least two prior treatments failed. Srivandana Akshintala leads it at the NIH Clinical Center. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.